Charles River director sells 573 shares at $285.24

Q: What insider transaction did Nancy C. Andrews report for CRL on this Form 4?

Nancy C. Andrews reported exercising 573 stock options for Charles River Laboratories (CRL) at $164.30 per share and acquiring 573 common shares, then selling all 573 shares at $285.24 per share on the same date.

Q: At what price were the Charles River Laboratories (CRL) shares sold in this Form 4?

The 573 CRL common shares acquired from the option exercise were reported sold at a price of $285.24 per share in the open market or a private transaction, according to the Form 4 sale code description.

Q: Was the CRL insider transaction made under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox was not checked, indicating the reported transactions were not affirmed as being made pursuant to a Rule 10b5-1 trading plan.

For CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

For CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL), director Nancy C. Andrews reported an option exercise and same-day sale. She exercised 573 stock options at an exercise price of $164.30 per share, acquiring 573 shares of common stock, and then sold 573 common shares at $285.24 per share. After these transactions, she reported 3,964 common shares held indirectly by trust. The Rule 10b5-1 trading-plan box was not checked.

Insider Trade Summary

Exercise and Sale: 573 shares ($69K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Andrews Nancy C

Role Director

Sold 573 shs ($163K)

Approx. gross sale proceeds $163K

Approx. exercise cost $94K

Approx. pre-tax spread $69K

Type	Security	Shares	Price	Value
Exercise	Stock Options (Right to Buy)	573	$0.00	$0.00
Exercise	Common Stock	573	$164.30	$94K
Sale	Common Stock	573	$285.24	$163K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Options (Right to Buy) — 0 contracts (Direct); Common Stock — 1,438 shares (Direct); Common Stock — 3,964 shares (Indirect, By Trust)

Key Figures

Options exercised: 573 shares Option exercise price: $164.30 per share Common shares sold: 573 shares +4 more

7 metrics

Options exercised 573 shares Stock options (right to buy) exercised into common stock

Option exercise price $164.30 per share Exercise price for 573 stock options

Common shares sold 573 shares Common stock sold following option exercise

Sale price $285.24 per share Price for sale of 573 common shares

Indirect holdings after transaction 3,964 shares Common stock held indirectly by trust after reported transactions

Option expiration date 2027-03-02 Expiration date of exercised stock options

Option grant exercise date 2021-03-02 Exercise date field for the derivative security

Key Terms

Stock Options (Right to Buy), Exercise or conversion of derivative security, indirect, By Trust, +1 more

5 terms

Stock Options (Right to Buy) financial

"security_title: Stock Options (Right to Buy)"

Exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

indirect financial

"ownership_type: indirect, nature_of_ownership: By Trust"

By Trust financial

"nature_of_ownership: By Trust"

Rule 10b5-1 regulatory

"Rule 10b5-1 trading-plan box was not checked"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nancy C. Andrews report for CRL on this Form 4?

Nancy C. Andrews reported exercising 573 stock options for Charles River Laboratories (CRL) at $164.30 per share and acquiring 573 common shares, then selling all 573 shares at $285.24 per share on the same date.

Did Nancy C. Andrews retain any Charles River Laboratories (CRL) shares after the reported sale?

Yes. After selling 573 common shares, Nancy C. Andrews reported an indirect holding of 3,964 CRL common shares, held by trust as of the transaction date.

What was the exercise price of the stock options reported by Nancy C. Andrews for CRL?

The stock options exercised by Nancy C. Andrews for Charles River Laboratories (CRL) had an exercise price of $164.30 per share, with 573 options exercised into an equal number of common shares.

At what price were the Charles River Laboratories (CRL) shares sold in this Form 4?

The 573 CRL common shares acquired from the option exercise were reported sold at a price of $285.24 per share in the open market or a private transaction, according to the Form 4 sale code description.

Was the CRL insider transaction made under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox was not checked, indicating the reported transactions were not affirmed as being made pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/20/2026 - 04:31 PM EDT Accepted by SEC EDGAR 08/20/2026 - 04:31 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Andrews Nancy C

(Last)

(First)

(Middle)

C/O CHARLES RIVER LABORATORIES

251 BALLARDVALE STREET

(Street)

WILMINGTON

MASSACHUSETTS

01887

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/18/2026		M		573	A	$164.3	2,011	D
Common Stock	08/18/2026		S		573	D	$285.24	1,438	D
Common Stock								3,964	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (Right to Buy)	$164.3	08/18/2026		M			573	03/02/2021	03/02/2027	Common Stock	573	$0	0	D

Explanation of Responses:

	/s/ Nancy C. Andrews	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR